TMCnet News
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapyMay 25, 2010 (Hugin via COMTEX) -- Novartis International AG / Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. * US Food and Drug Administration (FDA) extends priority review period by three months to September 2010, in line with previously announced expectations * FDA Advisory Committee meeting scheduled for June 10 to review data from FTY720 clinical trial program in MS * FTY720 clinical trial program is largest ever submitted to FDA to support approval of a new medicine in this therapeutic area Basel, May 25, 2010 - Novartis announced today that the US Food and Drug Administration (FDA) has extended by three months, to September 2010, its review period for the regulatory approval of FTY720 (fingolimod). FTY720 once-daily 0.5 mg has the potential to be the first oral therapy for relapsing multiple sclerosis (MS). A meeting of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee remains scheduled for June 10, 2010, to discuss the benefit/risk profile of this new active ingredient (New Molecular Entity). The FDA granted priority review status for FTY720 in February 2010, reducing the standard 10-month review period to six months, which was set to end on June 21, 2010. The extension was based on the FDA's request for further analysis of available data, which Novartis responded to and which triggered the three-month extension. The agency did not ask for additional clinical trials. Priority reviews are granted by the FDA for investigational medicines that could offer significant advances beyond current treatments or where no adequate therapy exists. "The announcement of this revised timeline is in line with our expectations, and reflects the comprehensive clinical program and resulting large amount of data to be reviewed in the NDA," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "MS is a leading cause of neurological disability in young adults and we are very committed to bringing new therapies to patients with this disabling condition." Data from the FTY720 MS clinical trial program, the largest ever submitted to the FDA to support approval of a new medicine in this therapeutic area, have demonstrated the significant benefits of FTY720 in reducing relapses in people with MS. Disclaimer The foregoing release contains forward-looking statements that can be identified by terminology such as "extension," "extends," "priority review," "scheduled," "extended," "potential," "set," "could," "expectations," "to be," "committed," or similar expressions, or by express or implied discussions regarding potential marketing approvals for FTY720, or the potential timing of such approvals, or regarding potential future revenues from FTY720. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with FTY720 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that FTY720 will be approved for sale in any market, or at any particular time. Nor can there be any guarantee that FTY720 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding FTY720 could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visithttp://www.novartis.com <http://www.novartis.com/>. # # # Novartis Media Relations Central media line: +41 61 324 2200 Eric Althoff Asa Josefsson Novartis Global Media Relations Novartis Pharma Communications +41 61 324 7999 (direct) +41 61 324 0161 (direct) +41 79 593 4202 (mobile) +41 79 515 2253 (mobile) [email protected] [email protected] <mailto:[email protected]> <mailto:[email protected]> e-mail: [email protected] <mailto:[email protected]> Novartis Investor Relations |Central phone: |+41 61 324 7944 | | --+---------------------+------------------+---------------+------------------- |Susanne Schaffert |+41 61 324 3769 |North America: | --+---------------------+------------------+---------------+------------------- |Pierre-Michel Bringer|+41 61 324 1065 |Richard Jarvis |+1 212 830 2433 --+---------------------+------------------+---------------+------------------- |John Gilardi |+41 61 324 3018 |Jill Pozarek |+1 212 830 2445 --+---------------------+------------------+---------------+------------------- |Thomas Hungerbuehler |+41 61 324 8425 |Edwin Valeriano|+1 212 830 2456 --+---------------------+------------------+---------------+------------------- |Isabella Zinck |+41 61 324 7188 | | --+---------------------+------------------+---------------+-------+----------- | | e-mail: [email protected]|e-mail: | <mailto:[email protected]> |investor.relations@nova| |rtis.com | |<mailto:investor.relati| |[email protected]> | --+---------------------+------------------+---------------+-------+----------- [HUG#1418321] --- End of Message --- Novartis International AG Postfach Basel null WKN: 904278;ISIN: CH0012005267; Media release (PDF): http://hugin.info/134323/R/1418321/368587.pdf SOURCE: Novartis International AG |